Bayer vorsichtig optimistisch bei Parkinson-Gentherapie
Bayer's BlueRock Therapeutics Establishes European Site For Cell Therapy Innovation - BlueRock Therapeutics LP
BlueRock Therapeutics Opens New MaRS Home for R&D | BrainStation®
BlueRock Therapeutics | Lifespan.io
Pathway to the Clinic: An Evening with the Stem Cell Podcast and BlueRock Therapeutics
Blue Rock Therapy and Wellness
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease
BlueRock in ophthalmology R&D alliance
BlueRock Therapeutics and bit.bio announce collaboration
BlueRock Therapeutics | LinkedIn
A bench-to-bedside story of BlueRock's investigational stem cell therapy for Parkinson's disease | Signals Blog
BlueRock Therapeutics Culture | Comparably
Ncardia and BlueRock Therapeutics Announce Licensing of Process Development Technologies
BlueRock Therapeutics | LinkedIn
BlueRock Therapeutic - Arktura
bit.bio and BlueRock Therapeutics announce collaboration to advance T cell (Treg) based therapies — Dynamk Capital
BlueRock Therapeutics Establishes Corporate Headquarters in Cambridge, Massachusetts and Bolsters Team to Support Rapid Growth and Development
BlueRock Therapeutics Culture | Comparably
BlueRock Therapeutics - B+H Architects
Bluerock unlikely to smooth Bayer's rocky road | Evaluate
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP
Bayer and Versant Ventures invest $225-million US to commercialize stem cell technology through BlueRock Therapeutics - MaRS Discovery District
Bayer trimmt Hoffnungsträger auf Effizienz - Entlassungen bei Bluerock
Bayer akquiriert Bluerock Therapeutics. Führende Position in der Zelltherapie ausgebaut - prozesstechnik online
